Collaboration and Licensing Revenue (Tables)

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following table summarizes the amounts recorded as revenue from continuing operations in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2020 and 2019.

	Three Months Ended   March 31,
	2020		2019
ZIOPHARM Oncology, Inc.	$	100	$	1,166
Oragenics, Inc.	198		201
Intrexon Energy Partners, LLC	—		977
Intrexon Energy Partners II, LLC	—		504
Fibrocell Science, Inc.	10,363		383
Harvest start-up entities (1)	—		2,723
Other	60		17
Total	$	10,721	$	5,971

(1)

For the three months ended March 31, 2019, revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

Summary of Deferred Revenue

Deferred revenue consisted of the following:

	March 31, 2020		December 31, 2019
Collaboration and licensing agreements	$	40,209	$	50,593
Prepaid product and service revenues	3,461		2,805
Other	348		435
Total	$	44,018	$	53,833
Current portion of deferred revenue	$	11,141	$	5,697
Long-term portion of deferred revenue	32,877		48,136
Total	$	44,018	$	53,833

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of March 31, 2020 and December 31, 2019, as well as the estimated remaining performance period as of March 31, 2020.

	Average Remaining Performance Period (Years)	March 31, 2020		December 31, 2019
Oragenics, Inc.	4.2	$	2,823	$	2,864
Intrexon Energy Partners, LLC	4.0	8,362		8,362
Intrexon Energy Partners II, LLC	4.7	12,843		12,843
Fibrocell Science, Inc.	1.0	7,359		17,697
Harvest start-up entities (1)	4.9	6,993		6,993
Other	2.5	1,829		1,834
Total		$	40,209	$	50,593

(1)

As of March 31, 2020 and December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.